Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | S100A9 | P06702 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.37 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2635603 | 0.86 | S100A9 (0.53) | CNR2S100A9RORCSCN3AEPAS1 | |
| SCHEMBL15627060 | 0.81 | ALDH1A1 (0.41) | CNR2S100A9ALDH1A1MAPTRORC | |
| SCHEMBL29553294 | 0.81 | ALDH1A1 (0.41) | CNR2S100A9ALDH1A1MAPTRORC | |
| SCHEMBL4181852 | 0.80 | TSHR (0.51) | ALDH1A1TSHRFFAR4 | |
| SCHEMBL2443453 | 0.78 | S100A9 (0.38) | CNR2S100A9ALDH1A1RORCSCN3A | |
| SCHEMBL1415662 | 0.78 | EPAS1 (0.47) | S100A9MCOLN3EPAS1 | |
| SCHEMBL1939505 | 0.77 | ALDH1A1 (0.63) | ALDH1A1MAPTTSHRMCOLN3L3MBTL1 | |
| SCHEMBL3884379 | 0.74 | EPAS1 (0.46) | CNR2S100A9ALDH1A1RORCEPAS1 | |
| SCHEMBL9978249 | 0.74 | PTPN1 (0.49) | ALDH1A1EPAS1 | |
| SCHEMBL9938331 | 0.74 | CNR2 (0.36) | CNR2S100A9ALDH1A1RORCSCN3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11229623-B2 | TRPV4 antagonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2022-01-25 | — | — | US | disclosed |
| US-11229623-B2 | TRPV4 antagonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2022-01-25 | — | — | US | disclosed |
| EP-3515887-B1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2021-07-07 | — | — | EP | disclosed |
| EP-3515887-B1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2021-07-07 | — | — | EP | disclosed |
| US-20200261411-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2020-08-20 | — | — | US | disclosed |
| US-10588891-B2 | TRPV4 antagonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-03-17 | — | — | US | disclosed |
| US-20190216774-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2019-07-18 | — | — | US | disclosed |
| US-20190216774-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2019-07-18 | — | — | US | disclosed |
| WO-2018055524-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2018-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10588891-B2 | TRPV4 antagonists | TRPV4, TRPV5, TRPV2 | NOTUM 2802/4885CNR2 89/4885S100A9 527/4885 |
| US-11229623-B2 | TRPV4 antagonists | TRPV4, TRPV5, TRPV2 | NOTUM 2802/4885CNR2 89/4885S100A9 527/4885 |
| US-20200261411-A1 | TRPV4 ANTAGONISTS | TRPV4, TRPV5, TRPV2 | NOTUM 2802/4885CNR2 89/4885S100A9 527/4885 |
| US-20190216774-A1 | TRPV4 ANTAGONISTS | TRPV4, TRPV5, TRPV2 | NOTUM 2802/4885CNR2 89/4885S100A9 527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.